Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RISANKIZUMAB-RZAA Cause Post procedural complication? 232 Reports in FDA Database

Visibly Younger Skin in Weeks

Synevra Lift & Lock — Swiss peptide serum + nutrients. 60-day money-back guarantee.

Discover Synevra

According to the FDA Adverse Event Reporting System (FAERS), 232 reports of Post procedural complication have been filed in association with RISANKIZUMAB-RZAA. This represents 0.4% of all adverse event reports for RISANKIZUMAB-RZAA.

232
Reports of Post procedural complication with RISANKIZUMAB-RZAA
0.4%
of all RISANKIZUMAB-RZAA reports
5
Deaths
79
Hospitalizations

How Dangerous Is Post procedural complication From RISANKIZUMAB-RZAA?

Of the 232 reports, 5 (2.2%) resulted in death, 79 (34.1%) required hospitalization, and 2 (0.9%) were considered life-threatening.

Is Post procedural complication Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RISANKIZUMAB-RZAA. However, 232 reports have been filed with the FAERS database.

What Other Side Effects Does RISANKIZUMAB-RZAA Cause?

Psoriasis (6,896) Drug ineffective (2,885) Pain (2,584) Fatigue (2,483) Arthralgia (2,419) Pruritus (2,311) Covid-19 (2,145) Death (1,700) Fall (1,666) Surgery (1,662)

What Other Drugs Cause Post procedural complication?

ADALIMUMAB (2,494) ETANERCEPT (318) CALCIUM\DEXTROSE\MAGNESIUM\SODIUM\SODIUM (244) UPADACITINIB (241) INFLIXIMAB (217) METHOTREXATE (188) TREPROSTINIL (174) HUMAN IMMUNOGLOBULIN G (159) PREDNISONE (157) CARBIDOPA\LEVODOPA (156)

Which RISANKIZUMAB-RZAA Alternatives Have Lower Post procedural complication Risk?

RISANKIZUMAB-RZAA vs RISDIPLAM RISANKIZUMAB-RZAA vs RISEDRONATE RISANKIZUMAB-RZAA vs RISEDRONIC ACID RISANKIZUMAB-RZAA vs RISPERDAL RISANKIZUMAB-RZAA vs RISPERDAL CONSTA

Related Pages

RISANKIZUMAB-RZAA Full Profile All Post procedural complication Reports All Drugs Causing Post procedural complication RISANKIZUMAB-RZAA Demographics